Literature DB >> 15540705

Ethical approval for national studies in Ireland: an illustration of current challenges.

M Smith1, F Doyle, H M McGee, D De La Harpe.   

Abstract

BACKGROUND: Ethical approval of research projects is, appropriately, an essential prerequisite in health settings. AIMS: This paper outlines difficulties encountered with procedures for gaining ethical approval for two multicentre surveys in Ireland.
METHODS: The experiences of two national surveys were documented.
RESULTS: Delays in processing ethics applications led to substantial delays in both surveys. Research ethics committees (RECs) assessed applications in an idiosyncratic manner.
CONCLUSION: In Ireland, there is currently no accepted mechanism for single location ethical approval for multicentre studies. Instead, they require separate approval from all participating centres. The challenges of this system of application to multiple committees are outlined in this paper, and possible solutions presented.

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2004        PMID: 15540705     DOI: 10.1007/bf02914559

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  3 in total

1.  Increase in observed mental health difficulties one year after acute coronary syndrome: general practitioner survey.

Authors:  F Doyle; H M McGee; R M Conroy; E Shelley; D De La Harpe
Journal:  Ir J Med Sci       Date:  2007-08-16       Impact factor: 1.568

2.  Nine-year comparison of presentation and management of acute coronary syndromes in Ireland: a national cross-sectional survey.

Authors:  Frank Doyle; Davida De La Harpe; Hannah McGee; Emer Shelley; Ronán Conroy
Journal:  BMC Cardiovasc Disord       Date:  2005-02-11       Impact factor: 2.298

3.  Impact of briefly-assessed depression on secondary prevention outcomes after acute coronary syndrome: a one-year longitudinal survey.

Authors:  Hannah M McGee; Frank Doyle; Ronán M Conroy; Davida De La Harpe; Emer Shelley
Journal:  BMC Health Serv Res       Date:  2006-02-13       Impact factor: 2.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.